Influenza, Human

Infectious Diseases
15
Pipeline Programs
8
Companies
15
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
7
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
583%
Small Molecule
117%
+ 9 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
OSELTAMIVIR PHOSPHATEApproved
oseltamivir
Unknown Company
oral2017
Roche
TAMIFLUApproved
oseltamivir phosphate
Roche
oral1999

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
3 programs
2
1
Fluad alonePhase 41 trial
Novartis Investigational H5N1 vaccinePhase 3Vaccine1 trial
Novartis Investigational H5N1 vaccinePhase 3Vaccine1 trial
Active Trials
NCT02091908Completed540Est. Apr 2015
NCT02107807Completed539Est. May 2015
NCT02225327Completed224Est. Jan 2014
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
TAMIFLU(oseltamivir)Phase 3Small Molecule1 trial
ProcalcitoninN/A1 trial
Active Trials
NCT02899065Completed200Est. May 2022
NCT00545532Completed228Est. May 2017
GC Biopharma
GC BiopharmaKorea - Yongin
4 programs
1
1
2
GC3110A vaccinePhase 3Vaccine1 trial
GC3110B vaccinePhase 3Vaccine1 trial
GC3114Phase 21 trial
GC3114Phase 11 trial
Active Trials
NCT03357263CompletedEst. Dec 2017
NCT03657719CompletedEst. Dec 2018
NCT02917304CompletedEst. May 2017
+1 more trials
DS
Daiichi SankyoChina - Shanghai
1 program
1
CS-8958Phase 31 trial
Active Trials
NCT00803595Completed1,002Est. Jun 2009
QT
Q TherapeuticsUT - Salt Lake City
1 program
1
Study group - quadrivalent recombinant hemagglutinin influenza vaccinePhase 3Vaccine1 trial
Active Trials
NCT03460743CompletedEst. Oct 2019
C
CureVacGermany - Tübingen
2 programs
1
1
F2C22C/DL001ZPhase 1/21 trial
GSK4382276A Dose level 1Phase 11 trial
Active Trials
NCT05446740Completed324Est. Mar 2024
NCT05823974Completed1,275Est. Dec 2024
Poolbeg Pharma
Poolbeg PharmaUK - London
1 program
1
POLB 001Phase 11 trial
Active Trials
NCT05765955Completed36Est. Dec 2022
Sanofi
SanofiPARIS, France
1 program
swab samplingN/A1 trial
Active Trials
NCT04244500Unknown2,500Est. Aug 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisFluad alone
Q TherapeuticsStudy group - quadrivalent recombinant hemagglutinin influenza vaccine
GC BiopharmaGC3110A vaccine
GC BiopharmaGC3110B vaccine
NovartisNovartis Investigational H5N1 vaccine
NovartisNovartis Investigational H5N1 vaccine
Daiichi SankyoCS-8958
Rocheoseltamivir
GC BiopharmaGC3114
CureVacF2C22C/DL001Z
CureVacGSK4382276A Dose level 1
Poolbeg PharmaPOLB 001
GC BiopharmaGC3114
Sanofiswab sampling
RocheProcalcitonin

Clinical Trials (15)

Total enrollment: 6,868 patients across 15 trials

NCT02225327NovartisFluad alone

MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Start: Oct 2013Est. completion: Jan 2014224 patients
Phase 4Completed
NCT03460743Q TherapeuticsStudy group - quadrivalent recombinant hemagglutinin influenza vaccine

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Start: Mar 2018Est. completion: Oct 2019
Phase 3Completed
NCT02917304GC BiopharmaGC3110A vaccine

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

Start: Oct 2016Est. completion: May 2017
Phase 3Completed
NCT02915809GC BiopharmaGC3110B vaccine

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Start: Oct 2016Est. completion: May 2017
Phase 3Unknown
NCT02091908NovartisNovartis Investigational H5N1 vaccine

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Start: Apr 2014Est. completion: Apr 2015540 patients
Phase 3Completed
NCT02107807NovartisNovartis Investigational H5N1 vaccine

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Start: Apr 2014Est. completion: May 2015539 patients
Phase 3Completed
NCT00803595Daiichi SankyoCS-8958

A Multinational Phase III Study of CS-8958 (MARVEL)

Start: Nov 2008Est. completion: Jun 20091,002 patients
Phase 3Completed
NCT00545532Rocheoseltamivir

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Start: Feb 2008Est. completion: May 2017228 patients
Phase 3Completed
NCT03657719GC BiopharmaGC3114

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects

Start: Oct 2018Est. completion: Dec 2018
Phase 2Completed
NCT05823974CureVacF2C22C/DL001Z

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Start: Apr 2023Est. completion: Dec 20241,275 patients
Phase 1/2Completed
NCT05446740CureVacGSK4382276A Dose level 1

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Start: Aug 2022Est. completion: Mar 2024324 patients
Phase 1Completed
NCT05765955Poolbeg PharmaPOLB 001

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Start: Jul 2022Est. completion: Dec 202236 patients
Phase 1Completed
NCT03357263GC BiopharmaGC3114

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

Start: Nov 2017Est. completion: Dec 2017
Phase 1Completed
NCT04244500Sanofiswab sampling

Burden of Influenza at Emergency Department (ED) Level in European Countries

Start: Jan 2020Est. completion: Aug 20202,500 patients
N/AUnknown
NCT02899065RocheProcalcitonin

Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department

Start: Mar 2018Est. completion: May 2022200 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
7h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
9h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
9h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
13h ago
$179K - $237K/yr

Technician, Operations, DSP/ Technicien(ne) des opérations, DSP

Verona Pharma
CAN - Prince Edward Island - Charlottetown
Yesterday
$47K - $79K/yr

HVAC Maintenance Technician

Verona Pharma
USA - Delaware - Millsboro (Intervet)
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)